Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Craig · SciRah

Researcher profile · Semantic Scholar

A. Craig

Share profile

A. Craig — researcher profile on SciRah

h-index: 19
Works: 61
Citations: 1,468

Most-cited papers

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
H. Kantarjian, V. Gandhi, J. Cortes, S. Verstovsek +12 more
2003Blood327 citations Open access
Semantic Scholar
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
F. Ravandi, E. Ritchie, H. Sayar, J. Lancet +32 more
2015The Lancet Oncology145 citations Open access
Semantic Scholar
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
J. Cortes, J. Lipton, D. Réa, R. Digumarti +7 more
2012Blood143 citations Open access
Semantic Scholar
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.
A. Gerds, M. Savona, B. Scott, M. Talpaz +22 more
2020Blood Advances91 citations Open access
Semantic Scholar
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
Jordi Cortés, R. Digumarti, P. Parikh, M. Wetzler +6 more
2013American journal of hematology/oncology67 citations Open access
Semantic Scholar
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
J. Nemunaitis, A. Mita, J. Stephenson, M. Mita +6 more
2012Cancer Chemotherapy and Pharmacology56 citations Open access
Semantic Scholar
Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib
Jordi Cortés, F. Nicolini, M. Wetzler, J. Lipton +9 more
2013Clinical Lymphoma, Myeloma & Leukemia54 citations Open access
Semantic Scholar
Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.
J. Cortes-Franco, H. J. Khoury, F. Nicolini, S. Corm +7 more
200949 citations
Semantic Scholar
Population Pharmacokinetics of Clofarabine, a Second‐Generation Nucleoside Analog, in Pediatric Patients With Acute Leukemia
P. Bonate, A. Craig, P. Gaynon, V. Gandhi +8 more
2004Journal of clinical pharmacology48 citations
Semantic Scholar
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
S. Verstovsek, R. Mesa, M. Talpaz, J. Kiladjian +9 more
2021Haematologica47 citations Open access
Semantic Scholar
Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors
H. J. Khoury, J. Cortes, M. Baccarani, M. Wetzler +5 more
2015Leukemia and Lymphoma35 citations
Semantic Scholar
Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.
J. Cortes-Franco, D. Raghunadharao, P. Parikh, M. Wetzler +8 more
200933 citations
Semantic Scholar
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors
F. Nicolini, H. Khoury, L. Akard, D. Réa +6 more
2013Haematologica30 citations Open access
Semantic Scholar
A Phase I Study of INNO-406 in Patients with Advanced Philadelphia (Ph+) Chromosome-Positive Leukemias Who Are Resistant or Intolerant to Imatinib and Second Generation Tyrosine Kinase Inhibitors.
H. Kantarjian, J. Cortes, P. le Coutre, A. Nagler +6 more
200730 citations
Semantic Scholar
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia
J. Lancet, G. Roboz, L. Cripe, G. Michelson +9 more
2015Haematologica28 citations Open access
Semantic Scholar
Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)
F. Ravandi, E. Ritchie, H. Sayar, J. Lancet +20 more
201424 citations
Semantic Scholar
Phase I trial of ARQ 501, an Activated Checkpoint Therapy (ACT) agent, in patients with advanced solid tumors
G. Shapiro, J. Supko, D. Ryan, L. Appelman +6 more
200524 citations
Semantic Scholar
Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)
C. Harrison, A. Gerds, J. Kiladjian, K. Döhner +5 more
2019Blood22 citations
Semantic Scholar
Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation
M. Binnerts, K. Otipoby, Brian T. Hopkins, T. Bohnert +7 more
201522 citations
Semantic Scholar
PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
J. Mascarenhas, A. Gerds, J. Kiladjian, K. Döhner +6 more
2021Blood21 citations
Semantic Scholar
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
N. Daver, H. Kantarjian, G. Garcia-Manero, E. Jabbour +10 more
201416 citations Open access
Semantic Scholar
A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib
A. Craig, H. Kantarjian, J. Cortes, D. Jones +7 more
200715 citations
Semantic Scholar
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia
F. Ravandi, E. Ritchie, H. Sayar, J. Lancet +20 more
2018Haematologica14 citations Open access
Semantic Scholar
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
N. Daver, H. Kantarjian, G. Garcia-Manero, E. Jabbour +17 more
2017Haematologica14 citations Open access
Semantic Scholar
Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in Imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation – Results of An Ongoing Multicenter Phase II Study.
J. Cortes, H. Khoury, S. Corm, F. Nicolini +7 more
200811 citations
Semantic Scholar
Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs).
F. Nicolini, J. Lipton, H. Kantarjian, M. Wetzler +6 more
201210 citations
Semantic Scholar
Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs).
L. Akard, H. Kantarjian, F. Nicolini, M. Wetzler +6 more
201210 citations
Semantic Scholar
Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib,
J. Cortes, F. Nicolini, M. Wetzler, J. Lipton +9 more
201110 citations
Semantic Scholar
Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation
A. Benichou, H. J. Khoury, S. Corm, F. Nicolini +3 more
20088 citations
Semantic Scholar
Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial
F. Ravandi, E. Ritchie, H. Sayar, J. Lancet +17 more
20167 citations
Semantic Scholar
Abstract C198: PDK1 inhibitors SNS-229 and SNS-510 cause pathway modulation, apoptosis and tumor regression in hematologic cancer models in addition to solid tumors
S. Hansen, J. Enquist, J. Iwig, M. Binnerts +3 more
20157 citations
Semantic Scholar
Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs).
M. Wetzler, H. Kantarjian, F. Nicolini, J. Lipton +5 more
20127 citations
Semantic Scholar
Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial.
J. Cortes, H. Khoury, S. Corm, F. Nicolini +6 more
2016Journal of Clinical Oncology5 citations
Semantic Scholar
VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia
F. Ravandi, E. Ritchie, H. Sayar, S. Strickland +16 more
20125 citations
Semantic Scholar
Subcutaneous Omacetaxine (OM) Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients Following Multiple Tyrosine Kinase Inhibitor (TKI) Failure
J. Cortes, M. Wetzler, Jeffrey M. Lipton, F. Nicolini +8 more
20105 citations
Semantic Scholar
The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study
J. Palmer, R. Mesa, Stephen T. Oh, R. Rampal +10 more
2021Blood4 citations Open access
Semantic Scholar
Long-Term Follow-up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
H. Kantarjian, J. Lipton, M. Baccarani, F. Nicolini +6 more
20124 citations
Semantic Scholar
Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19
J. Cafardi, C. Miller, H. Terebelo, Chad Tewell +13 more
2022JAMA Network Open3 citations Open access
Semantic Scholar
Safety Analysis of Pacritinib in Patients with Myelofibrosis and Severe Thrombocytopenia
J. Mascarenhas, C. Harrison, A. Gerds, J. Prchal +7 more
2021Blood3 citations Open access
Semantic Scholar
Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study
U. Krug, F. Ravandi, E. Ritchie, H. Sayar +21 more
20153 citations
Semantic Scholar
Downregulation of the Common Cytokine Receptor Subunit Beta c by Omacetaxine in CML: A Potential Molecular Mechanism to Overcome Cytokine-Mediated Resistance against BCR-ABL-Inhibitors.
T. Klag, Nicolai Härtel, T. Schenk, A. Craig +2 more
20093 citations
Semantic Scholar
Pharmacokinetics of synthadotin (ILX651), a novel tubulin polymerization inhibitor, in patients with solid tumors
P. Bonate, S. Ebbinghaus, J. Eder, A. Mita +6 more
20043 citations
Semantic Scholar
Induction of Complete Remission Using Single Agent Clofarabine in a Patient with Primary Refractory Acute Myeloblaste Leukemia
Dou-Er Dan, K. Watkins, A. Levine, Jane M Weiss +2 more
2003Leukemia and Lymphoma2 citations
Semantic Scholar
Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study
J. Lancet, F. Ravandi, E. Ritchie, H. Sayar +17 more
20151 citations
Semantic Scholar
Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
N. Daver, H. Kantarjian, S. Pierce, M. Brandt +10 more
20141 citations
Semantic Scholar
Predictive factors associated with achievement of major cytogenetic response (MCyR) to omacetaxine mepesuccinate among patients with chronic phase chronic myeloid leukemia (CML-CP).
M. Wetzler, H. Kantarjian, F. Nicolini, J. Lipton +5 more
20131 citations
Semantic Scholar
Blast Phase Chronic Myeloid Leukemia: A Pooled Analysis of Subcutaneous Omacetaxine Mepesuccinate in Treatment-Resistant Patients
H. Khoury, J. Cortes, M. Wetzler, J. Lipton +5 more
20121 citations
Semantic Scholar
A phase I study of INNO-406, a dual inhibitor of Abl/Lyn kinases, in adult patients with imatinib-resistant or intolerant Philadelphia chromosome positive (Ph+) leukemias
H. Kantarjian, J. Cortes, A. Craig, S. O'Brien +8 more
20071 citations
Semantic Scholar
218 A phase I and pharmacokinetic trial ARQ 501, an Activated Checkpoint Therapy (TM) agent, in patients with advanced solid tumors
A. Craig, G. Shapiro, D. Ryan, J. Eder +6 more
20041 citations
Semantic Scholar
Clofarabine plus cytarabine (ara-C) is an active induction regimen for newly diagnosed patients (pts) ≥ age 50 with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
S. Faderl, V. Gandhi, F. Giles, E. Estey +6 more
2004Journal of Clinical Oncology1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

H. Kantarjian×29
Invite
H. Kantarjian — researcher profile on SciRah
J. Cortes×26
Invite
J. Cortes — researcher profile on SciRah
F. Nicolini×16
Invite
F. Nicolini — researcher profile on SciRah
J. Lipton×12
Invite
J. Lipton — researcher profile on SciRah

×12

Invite

A. Benichou — researcher profile on SciRah

Invite

M. Wetzler — researcher profile on SciRah

Invite

F. Ravandi — researcher profile on SciRah

M. Baccarani×11

Invite

M. Baccarani — researcher profile on SciRah

Invite

J. Smith — researcher profile on SciRah

Invite

L. Akard — researcher profile on SciRah

Invite

A. Hochhaus — researcher profile on SciRah

Invite

J. Lancet — researcher profile on SciRah